Ftse Mib
35.355,87
0,58%
DAX
18.869,36
0,78%
S&P 500
5.305,36
1,12%
NASDAQ
16.740,46
1,39%
Bitcoin
66.093,83
7,39%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Kura Oncology Inc (KURA) Kura Oncology Inc (KURA) Notizie

KURA

Kura Oncology (KURA)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:KURA
DataOraFonteTitoloSimboloCompagnia
14/05/202413:30GlobeNewswire Inc.Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AMLNASDAQ:KURAKura Oncology Inc
08/05/202413:30GlobeNewswire Inc.Kura Oncology to Participate in Bank of America Securities Healthcare ConferenceNASDAQ:KURAKura Oncology Inc
03/05/202413:30GlobeNewswire Inc.Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KURAKura Oncology Inc
02/05/202422:05GlobeNewswire Inc.Kura Oncology Reports First Quarter 2024 Financial ResultsNASDAQ:KURAKura Oncology Inc
25/04/202413:30GlobeNewswire Inc.Kura Oncology to Report First Quarter 2024 Financial ResultsNASDAQ:KURAKura Oncology Inc
22/04/202413:30GlobeNewswire Inc.Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AMLNASDAQ:KURAKura Oncology Inc
10/04/202413:30GlobeNewswire Inc.Kura Oncology to Participate in Stifel Targeted Oncology ForumNASDAQ:KURAKura Oncology Inc
06/03/202413:30GlobeNewswire Inc.Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell CarcinomaNASDAQ:KURAKura Oncology Inc
27/02/202422:52Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:KURAKura Oncology Inc
27/02/202422:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KURAKura Oncology Inc
27/02/202422:01GlobeNewswire Inc.Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:KURAKura Oncology Inc
26/02/202413:30GlobeNewswire Inc.Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid LeukemiaNASDAQ:KURAKura Oncology Inc
22/02/202413:30GlobeNewswire Inc.Kura Oncology to Participate in Three Upcoming Investor ConferencesNASDAQ:KURAKura Oncology Inc
20/02/202413:30GlobeNewswire Inc.Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:KURAKura Oncology Inc
15/02/202422:01Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:KURAKura Oncology Inc
15/02/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:KURAKura Oncology Inc
14/02/202423:58Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:KURAKura Oncology Inc
09/02/202423:21Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:KURAKura Oncology Inc
31/01/202423:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KURAKura Oncology Inc
30/01/202422:10Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KURAKura Oncology Inc
30/01/202413:00GlobeNewswire Inc.Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid LeukemiaNASDAQ:KURAKura Oncology Inc
24/01/202413:00GlobeNewswire Inc.Kura Oncology Announces Oversubscribed $150 Million Private PlacementNASDAQ:KURAKura Oncology Inc
08/12/202313:30GlobeNewswire Inc.Kura Oncology’s Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Master Clinical TrialNASDAQ:KURAKura Oncology Inc
28/11/202313:30GlobeNewswire Inc.Kura Oncology to Participate in the JMP Securities Hematology and Oncology SummitNASDAQ:KURAKura Oncology Inc
02/11/202321:39Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:KURAKura Oncology Inc
02/11/202321:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KURAKura Oncology Inc
02/11/202321:01GlobeNewswire Inc.Kura Oncology Reports Third Quarter 2023 Financial ResultsNASDAQ:KURAKura Oncology Inc
02/11/202312:30GlobeNewswire Inc.Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLCNASDAQ:KURAKura Oncology Inc
30/10/202312:30GlobeNewswire Inc.Kura Oncology to Participate in Three Upcoming Investor ConferencesNASDAQ:KURAKura Oncology Inc
26/10/202322:05GlobeNewswire Inc.Kura Oncology to Report Third Quarter 2023 Financial ResultsNASDAQ:KURAKura Oncology Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:KURA

La tua Cronologia

COIN
ETHSCBTC
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network